Outcomes of patients with bone metastases from differentiated thyroid cancer
AUTOR(ES)
Califano, Inés, Deutsch, Susana, Löwenstein, Alicia, Cabezón, Carmen, Pitoia, Fabián
FONTE
Arch. Endocrinol. Metab.
DATA DE PUBLICAÇÃO
2018-02
RESUMO
ABSTRACT Objective Bone metastases (BM) from differentiated thyroid cancer (DTC) are associated with poor survival rates. Due to the low frequency of this entity, we performed a multicentric retrospective study that aimed to evaluate the presentation, outcome and causes of death in this population. Subjects and methods We reviewed file records from 10 databases. BM were diagnosed by: i) biopsy and/or ii) radioiodine (RAI) bone uptake + elevated thyroglobulin (Tg) levels and/or c) bone uptake of 18-FDG in the PET-CT scan + elevated Tg levels. Results Fifty-two patients with DTC were included (44% male, mean age 54 years); 58% had papillary histology. BM were synchronous with DTC diagnosis in 46% of the participating cases. BM were symptomatic in 65% of the cases. Multiple BM were present in 65% of patients, while simultaneous metastatic disease in additional sites was found in 69%. Ninety-eight percent of patients received treatment for the BM, which included RAI therapy in 42 patients; 30 of them received cumulative RAI doses that were larger than 600 mCi 131I. The mean follow-up after a BM diagnosis was 34 months. The 2- and 5-year survival rates after diagnosis of the first BM were 64% and 38%, respectively. The status on the last evaluation was DTC-related death in 52% of the patients; 26% of them died from direct complications of BM or their treatments. Conclusion BM are usually radioiodine-refractory and are associated with a short overall survival, although most of the patients died of causes not directly related to the BM.
Documentos Relacionados
- Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
- Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas.
- Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases.
- Impact of historic histopathologic sample review on the risk of recurrence in patients with differentiated thyroid cancer
- Improving care of patients with low-risk differentiated thyroid carcinoma